The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Well, then let's get organised and do something practical. If we truly believe that the fee structure is holding back our investments, then let's get organised to file a shareholder resolution for the next AGM in 2025. That at least can apply some pressure and be the focal point for any shareholder activism we undertake in the next year.
Feel embarrassed I haven't been following the wider macro issue. Had no idea that this became such a contentious culture war issue in the States. Completely explains the SP right now.
Times have a piece out now covering what's happening.
If that's your takeaway after looking at the investment portfolio, then you might want to revaluate your research skills. Mellon might be greedy, but saying this is a "get rich" scheme is a stretch.
I would challenge that there's been great news. We've had production pilots, small financing rounds, and limited regulatory approval. Until there is an actual market ready product, all of this is still a completely speculative play. None of what's been announced has been particularly ground breaking.
Not sure if Mellon and co. are to blame really - putting the terrible payment structure outside, we've had (1) a complete evaporation in biotech funding in 2022 and 2023 and (2) the technology hasn't progressed as quickly as expected - ultimately its still completely speculative and the reality is that it might never actually reach cost parity.
I look at some of the other speculative technology plays I invested in: Plug Power, Proterra, ASTS - and those have performed far worse/or simply gone under. Agronomics was created during a SPAC craze where people were investing in absolutely anything - how many of those have completely imploded?
Things could be far far worse. We have a solid portfolio of companies spread out across a number of different subsectors. If you believe that the technology will work - then stay invested. If not, might be worth cutting your losses now.
Saw that too and thought of this. Over saturated vegan meat market with the distinct lack of protein. Think it makes the case for lab grown meat even more. Especially given price rises in meat atm. Still think appetite is there, but current options are just not appealing.
It clearly does. They put forward unfunded tax cuts which will cause the BOE to raise interest rates further, which will impact more on speculative stocks. We're getting double hammered by what's happening in the US.
What is your holding then skier1? Seems you'd like to sell now then buy when the SP is low. If we could all accurately predict price movements in the stock market, we would be rich. Who knows what tomorrow will bring. The investment thesis for lab grown meat hasn't changed. Wider market conditions have. There is no logic in selling now. The portfolio companies are strong. Your entire thesis rests on the performance of plant based alternatives, which is a completely different and saturated market. There is a reason why Nestle just announced entry into this space with lab-grown milk just weeks ago.
Why thank you skier1 for your insightful take based on strock market chart astrology. Care to explain why you think a company would go for a 1:1 SP to the cash it has in the bank? That is what a 4p SP would be assuming every single investment ANIC has already made is valued at zero.
It could be much worse. We could be in a position where ANIC companies collapse because they don't have the necessary funds to scale up due to market conditions. All the firms received a pretty hefty cash injection so I reckon we have enough to ride this bear market out. ANIC is also storing what, 40-50m in the bank?
I reckon we're still going to be in a bear market for at least 2 - 3 years. Structural energy issues won't go away and it's impacting spend everywhere, causing a snowball effect.
I'm incredibly happy with how ANIC is performing given wider market environments. It's currently 50% of my portfolio. I'm also happy with the shift in focus. There will be IP needed in the production process and as Horti mentions, the scale of facilities needed will be absolutely vast.